Ahmedabad-based Cadila Healthcare’s US subsidiary, Zydus Pharma USA Inc, has received approval from the United States Food and Drugs Administration (US FDA) to market a generic pain reliever Ultracet in strengths of 32.5 mg and 37.5 mg. The drug is used in the management of moderate to severe pain and widely prescribed to arthritic patients.
The company recently in the month of August received a tentative approval from the US FDA for Aripiprazole orally disintegrating tablets in the strengths of 10 mg, 15 mg, 20 mg and 30 mg. The drug is an anti-psychotic medication used in the treatment of schizophrenia.
Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
